MedTrace Logo

Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients

NCT06807021 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-05-04

No results posted yet for this study

Summary

The goal of this study is to see how an ingredient called kynurenic acid (which we named "FS2") affects scar formation in people with burn injuries that need skin graft surgery. A cream with FS2 will be used on both the area where the skin graft was placed and the area where the skin was taken (donor site). The cream will be applied after the skin has healed. This study will help us understand if FS2 is safe and effective for mitigating skin scar formation in burn patients.

Conditions

  • Burn Scar
  • Burn Wound

Interventions

DRUG

IP1 control cream (Vehicle base)

Without FS2

DRUG

IP2 - 0.5% w/w FS2

FS2 in pharmaceutical compounding base

Sponsors & Collaborators

  • Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

    collaborator NETWORK

  • Birch BioMed Inc

    lead INDUSTRY

Principal Investigators

  • Carlos Camozzi, MD, PHD · BirchBioMed Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2026-10-15
Completion
2026-11-06

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06807021 on ClinicalTrials.gov